Posted by Michael Wonder on 09 Oct 2016
NICE backs use of Forxiga in triple therapy for diabetes
7 October 2016 - NICE has now published final draft guidelines endorsing NHS use of AstraZeneca's Forxiga for treating type II diabetes as part of a 'triple therapy'.
In other words, if the recommendations are mandated, then patients whose blood sugar levels remain uncontrolled despite already taking taking two drugs, then Forxiga (dapagliflozin) can be added as a third.
Two other medicines, Jardiance (empagliflozin) and Invokana (canagliflozin), are already routinely available on the NHS options for triple therapy, and all three are now recommended on their own, if a person can't use metformin or other specific drugs, or in combination with metformin.
